Matinas BioPharma Holdings, Inc. - MTNB STOCK NEWS

Matinas BioPharma (MTNB) announced significant clinical results for MAT2203, an oral formulation of amphotericin B, at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Dr. Marisa H. Miceli presented a compassionate use case where MAT2203 effectively treated a patient with a rare, resistant fungal infection (Rhodotorula mucilaginosa) after traditional IV treatment led to severe kidney toxicity. The patient showed substantial clinical improvement, tolerated MAT2203 well over six months, and completed therapy with no renal adverse effects. This success highlights MAT2203's potential as a safer, outpatient alternative for patients requiring long-term antifungal treatment. Matinas is preparing for Phase 3 trials with the FDA to further evaluate MAT2203's efficacy for invasive fungal infections, though it remains unapproved globally.

Matinas BioPharma (MTNB) reported 2022 financial results, posting $3.2 million in revenue, a substantial increase from $33,000 in 2021, attributed to its collaboration with BioNTech. Total costs rose to $27.8 million, reflecting advancements in clinical development. The company's net loss decreased to $21.0 million from $23.7 million year-over-year. Key milestones ahead include FDA meetings regarding MAT2203 for invasive fungal infections and potential non-dilutive funding from BARDA or NIH. Promising data from ongoing collaborations with BioNTech and National Resilience are expected in 2023, enhancing the application of their lipid nanocrystal platform.

Matinas BioPharma Holdings, Inc. (MTNB) will report its 2022 financial results on March 15, 2023, after market close. A conference call hosted by management will occur at 4:30 p.m. ET to discuss the results and provide a business update. The company focuses on innovative intracellular delivery of nucleic acids and small molecules via its lipid nanocrystal (LNC) platform, aimed at enhancing patient access and clinical impact. Matinas is developing its internal product portfolio and collaborating with pharmaceutical companies to leverage its LNC technology, which shows potential in overcoming current delivery challenges in therapies such as mRNA and vaccines.

Matinas BioPharma (NYSE American: MTNB) has announced that its oral formulation of amphotericin B, MAT2203, will be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) on April 18, 2023. The company is developing MAT2203 for treating invasive fungal infections with a focus on reducing toxicity associated with traditional intravenous amphotericin B. Presentations will cover a Phase II trial for cryptococcal meningitis and a case of osteomyelitis treatment. Matinas aims to leverage its lipid nanocrystal technology for broader applications, improving patient access and clinical outcomes.

Matinas BioPharma (MTNB) reported a successful 2022, validating its lipid nanocrystal (LNC) platform for delivering therapies, particularly MAT2203 for fungal infections. The company has partnerships with BioNTech and National Resilience, aiming for initial in vivo data by mid-2023. With approximately $28.8 million in cash, Matinas expects to fund operations through Q2 2024. The firm plans to engage with BARDA and the FDA regarding MAT2203's Phase 3 study. Key developments include a focus on nucleic acids and the potential for expanding internal product pipelines.